Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Sandvik in connection with a EUR 500 million loan from the European Investment Bank (EIB)Vinge has advised Sandvik in connection with a EUR 500 million loan from the European Investment Bank (EIB)
Mandate

Vinge has advised Sandvik in connection with a EUR 500 million loan from the European Investment Bank (EIB)

January 20, 2023 Banking and Finance

Vinge has advised Sandvik AB (publ) and Sandvik Treasury AB (publ) in connection with the entry into of a EUR 500 million loan agreement with the European Investment Bank (EIB). The loan will support Sandvik’s investments in research and development (R&D), which include advanced solutions in component manufacturing as well as solutions for electrification and automation in mining and infrastructure.

The loan has a seven-year tenor and will support Sandvik’s R&D investment plans until 2025.

Sandvik is a global, high-tech engineering group providing solutions that enhance productivity, profitability and sustainability for the manufacturing, mining and infrastructure industries.

Vinge’s team consisted of Albert Wållgren, Arvid Weimers and Karl-Gustaw Tobola.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025